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ABSTRACT 
Although there is evidence for the involvement of genes of serotonergic and 
dopaminergic systems in the manifestation of the Behavioural and Psychological 
Symptoms in Dementia (BPSD), genetic association studies are contradictory. We 
used 1008 probable AD patients from the UK and applied a Multiple Indicators 
Multiple Causes (MIMIC) approach to investigate the effect of 11 polymorphisms in 
the serotonergic and dopaminergic systems, on four behavioural sub-phenotypes, 
namely  “psychosis”,” moods”, “agitation” and “behavioural dyscontrol”, as well as 
on 12 NPI items. Significant findings included the association of DRD1 A48G with 
“psychosis” (p=0.037), the association of DAT1 VNTR with “agitation” (p=0.006) 
and the association of DRD4 with “moods” sub-phenotype (p=0.008). In addition, 
associations were identified between DRD1 A48G and DAT1 VNTR with aberrant 
motor behaviour (AMB) symptoms (p=0.001 and p=0.015 respectively), between 
DRD4 and sleep disturbances (p=0.018) and between 5HTTLPR and apathy 
(p=0.033). Finally, significant interactions were observed between COMT Val158Met 
and 5HTTLPR with “psychosis” (p=0.026), between HTTLPR and STin2 with 
“psychosis” (p=0.005), between DAT1 3’UTR VNTR and COMT Val158Met with 
“agitation” (p=0.0001) and between DAT1 3’UTR VNTR and 5HTTLPR with the 
“moods” factor (p=0.0027). The complexity of the interrelations between genetic 
variation, behavioural symptoms and clinical variables was efficiently captured by 
this MIMIC model. 
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INTRODUCTION 
Behavioural and psychological symptoms such as hallucinations, agitation or 
depression occur in the majority of people with Alzheimer’s Disease and are 
associated with considerable morbidity to patients and distress to carers (1-3). Family, 
linkage and genetic association studies (4-7) suggest a genetic component to those 
Behavioural and Psychological Symptoms in Dementia (BPSD). Studies investigating 
BPSD have focused on the dopaminergic and serotonergic neurotransmission, as both 
systems have been implicated in many aspects of human and animal behaviour and 
are potential targets for treatment of BPSD and psychiatric disorders.  A number of 
genetic association studies have examined genes from  these systems, including the 
serotonin receptor genes 5HT2A and 5HT2C, the serotonin transporter  gene (SERT), 
the dopamine receptors DRD1-4 genes, the dopamine transporter 1 gene (DAT) the 
Catechol-O-methyl transferase  gene (COMT) and the Monoamine Oxidase A gene 
(MAOA) in an effort to define the genetic basis of BPSD, but conflicting results have 
been reported (8-25). Inconsistent findings may reflect the small number of patients 
examined, which in general do not exceed 500, as well as the various measures to 
define BPSD and differences in clinical population studies, particularly in relation to 
disease stage and use of psychotropic medication.  BPSD are complex and inter-
related and the effects of allelic variants are likely to be individually small, 
highlighting the need for larger and more systematic approaches and more consistent 
definitions of abnormal behaviour.  
This study aimed to investigate associations between risk alleles/genotypes and the 
presence of behavioural symptoms and sub-phenotypes, using data on eleven 
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polymorphisms from ten genes, in a large cohort (n = 1008) of patients with probable 
AD.  In addition to associations between genes and BPSD, potential interactions 
between polymorphisms which may affect the expression of these behavioural 
symptoms were investigated. Interactions were also investigated between the X-linked 
genes and gender to capture sex-specific effects. All of the polymorphisms were 
chosen because they have been previously associated with neuropsychiatric 
conditions such as depression or schizophrenia and all of them bar one (DRD2 Taq1) 
have been previously associated with behavioural symptoms in AD.   
The fact that behavioural symptoms in AD tend to co-occur has led to the suggestion 
that distinct behavioural sub-phenotypes exist.  We have previously proposed a 
Multiple Indicators Multiple Causes (MIMIC) model to capture the complexity of the 
interrelations between behavioural symptoms, sub-phenotypes and clinical variables, 
in the same dataset (26). Four behavioural sub-phenotypes, namely "psychosis", 
"moods", "agitation" and "behavioural dyscontrol" were identified and their 
associations with each other, as well as with covariates such as cognitive impairment, 
gender, age of onset and disease duration and each other were modelled. MIMIC 
models have been successfully applied in geriatric research (27-29), psychiatric 
studies (30;31)  as well gene X environment studies (32). In the current study we 
aimed to use this model as a platform to test the association between risk 
alleles/genotypes with these behavioural symptoms and sub-phenotypes in the 
presence of covariates. This is a powerful approach which allows us to perform a 
simultaneous analysis of the entire system of variables, by forming specific 
hypotheses.  Such systematic analysis will help shed light into the biological nature of 
these common and disabling symptoms in AD. 
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METHODS 
Subject cohorts 
We have used a UK cohort comprising of more than 1000 participants from the 
Medical Research Council Genetic Resource for Late-onset AD.  AD patients were 
ascertained by four collaborating centres, comprising the Institute of Psychiatry in 
London, Cardiff University School of Medicine in Cardiff, Trinity College in Dublin 
and Cambridge University in Cambridge. All individuals were unrelated white 
European, recruited through secondary care services and diagnosed with probable AD 
in accordance with the National Institute of Neurological and Communication 
Disorders and Stroke/ Alzheimer’s disease and Related Disorders Association clinical 
diagnostic criteria (33). The 12-item Neuropsychiatric Inventory (NPI) (34) was used 
to assess prevalence and severity of BPSD in participants. Details on the NPI and the 
assessment of patients can be found in (26).  Ethical permission was obtained from 
the relevant Research Ethics Committees. 
 
Genotyping analyses 
DNA was available for all 1008 patients. 
Genotyping of Single Nucleotide Polymorphisms  (SNPs) 
The genotypes of the 5HT2A C102T (rs6313), 5HT2C Cys23Ser (rs6318) , DRD1 -
48A/G (rs4532), DRD2 A1 allele (rs1800479), DRD3 Gly9Ser (rs6280) and  COMT 
Val158Met (rs4680) polymorphisms were determined by allelic discrimination assays 
based on fluorogenic 5’ nuclease activity: TaqMan  Single Nucleotide Polymorphism 
(SNP) Genotyping Assay (Applied Biosystems,). SNP-specific primers and probes 
were designed and assays were performed according to the manufacturer's 
instructions. 
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 Genotyping of Variable Number Tandem Repeats (VNTRs)  
Genotyping of the 5HTTLPR, STin2, MAOA and DAT1 VNTRs  was performed 
using protocols described elsewhere with few modifications (8;35-37) (Supplement 
Methods 1). 
  
Statistical analyses 
All polymorphisms were investigated for significant departure from the Hardy-
Weinberg Equilibrium (HWE) using the program PLINK (38). Associations between 
risk alleles/genotypes for each SNP were examined using the same MIMIC model 
method described in (26).  Structural Equation Modelling (SEM) analyses were 
conducted in Mplus Version 5.1 (39) using the robust maximum likelihood (MLR) 
estimator. MLR estimates the parameters by maximum likelihood and the standard 
errors by asymptotically robust methods using the asymptotic covariance matrix, 
which is appropriate when using non- normally distributed indicator variables such as 
the NPI items. Disease duration, cognitive impairment as measured by the Mini 
Mental State Examination   (MMSE) (40) (1=  MMSE scores 0-10, 2= MMSE scores 
11-20, 3= MMSE scores 21-28), current age or age of onset (due to co-linearity 
between age) gender and psychotropic medication were used as covariates in the 
MIMIC model. Patients were classified as drug-naïve if they were not receiving any 
antipsychotic, antidepressant, sedative or anxiolytic medication. In order to avoid 
issues of multiple testing, one genetic model was tested for each SNP by adding in the 
MIMIC model the risk or protective allele implicated in previous studies. For the 
5HTTLPR polymorphism we investigated for the presence of short allele or genotype 
(S or SS & LS), whereas for STin2 we examined the association between BPSD and 
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presence of (12R) repeats. For MAOA we sought for associations between BPSD and 
the presence of high activity (4 repeats) alleles of the promoter VNTR.  For the DAT1 
40bp VNTR we sought for associations between BPSD and the presence of either 9 or 
10 repeats (9R or 10R) and finally for the 48bp repeat in exon 3 of DAT1, 
associations were sought between BPSD and the presence of 7 repeats (7R), 4 repeats 
(4R) or 2 repeats (2R).  
Analysis took place in three stages. An initial model was developed without 
polymorphisms (investigating the presence of covariates). A second model was then 
constructed where all polymorphisms were added simultaneously in the presence of 
covariates followed by stepwise backward regression. This would highlight any 
potential changes in the association of covariates with behavioural sub-
phenotypes/symptoms in the presence of genetic variation and would also reveal the 
amount of variation on each sub-phenotype/symptom attributable to the 
polymorphisms. Finally, a complete model was built which included interactions 
between polymorphisms and between polymorphisms and gender. All three models 
were built using stepwise backward regression. In each step the fit of the simpler 
model was compared to that of the more complex model by using Satorra-Bentler 
scaled chi-square test between the two models as described in 
http://www.statmodel.com/chidiff.shtml. To calculate this test the scaling correction 
factor, supplied by Mplus, for each model is used. The test of chi-square difference 
continued until the final fitted model was no longer significant using an alpha level of 
0.05. Satorra-Bentler scaled chi-square test was also used to test which of the three 
models (simple model without genetic information, model with genetic information, 
and final model with genetic interactions) had the best fit. 
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Direct paths between polymorphisms or covariates and the factor indicators (i.e. NPI 
items) which indicated differences in the factor indicators (e.g. delusions) that can be 
attributed to each polymorphism/covariate after controlling for the factor  also know 
as Differential Item Functioning (DIF), were also estimated as described before (26). 
This process was used in order to identify direct associations between a 
polymorphisms and symptoms.  After this, a significant effect of the polymorphism 
on the latent variable would imply differences on the latent mean score. To simplify 
interpretation, associations were performed assuming no directionality between the 
factors but measuring their correlations after adjusting for the rest of the variables 
instead.   
As described in Proitsi et al., (2009) (26), the χ2 test relative to the degrees of 
freedom, the root mean squared error of approximation (RMSEA), and Comparative 
Fit Index (CFI) were used to evaluate fit of each model tested.  Modification indices 
(MI) were included if they were >8 (MI>3.84 for 1 degree of freedom are indicative 
of significant drop in the χ2 if the path is freed) and whether they were accepted from 
a theoretical standpoint.  
Power Calculations 
Power calculations were performed using the program QUANTO (41). 
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RESULTS 
The key demographic characteristics of the 1008 patients are presented on Table 1 
and the frequencies of the alleles examined for each polymorphism are presented in 
Table 2. Power calculations were made using the allele frequencies in Table 2. For a 
quantitative trait design and unrelated individuals, assuming a type I error rate of 0.05 
and using a two-sided test, this study gave us >75% power to detect the effect a gene 
with a minor allele frequency of 0.1 explaining a 1% proportion of variance of a trait 
and >75% power to detect a significant interaction between two genes with a minor 
allele frequencies of 0.1 which explains 1% proportion of variance. These power 
values were obtained assuming a recessive mode of inheritance, and are therefore 
greater when dominant or additive models were used. 
 
Multiple Indicators Multiple Causes (MIMIC) models 
A. MIMIC model using covariates only 
An initial model to assess the effect of covariates on the factor structure was created 
using the method described in  Proitsi et al., (2009) (26). This cohort utilised the 12 
item NPI  (instead of the 10 item NPI used in (26)), controlled for use of  
psychotropic medication, did not use a disease duration cut-off point of 2.5 years and  
included  only  patients from the MRC Genetic Resource Centre for Late-Onset AD. 
In addition correlations rather than directions between the four factors were modelled 
and therefore some small differences to the previously published model were 
observed (Supplementary Table 1).   
Supplementary Table 1 and Supplementary Figure 1 show the associations between 
covariates and the four factors. Stepwise backwards regression was used as described 
to generate the model with the best fit. Overall the model had a good fit (χ2=95.459, 
df=85, p=0.225, RMSEA=0.011, CFI=0.993), and the five covariates (Gender, 
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age/age of onset, MMSE, disease duration and psychotropic medication) explained 
14.3% of the variability of “psychosis” factor, 8.6% of the variability of “agitation” 
factor, 13.3% of the variability of “moods” factor and 32% of the variability of 
“behavioural dyscontrol” factor. 
 
B. MIMIC model using covariates and polymorphisms. 
A MIMIC model was then built by adding simultaneously all the polymorphisms 
described in Table 2. For the DAT1, HTTLPR and DRD4 polymorphisms individual 
models were first tested and only the alleles of each polymorphism showing 
significant associations or trends were added in the final model. Stepwise backward 
regression was used as before.  
Adding the polymorphisms in the model indicated a significant association between 
DRD1 A48G G allele and lower “psychosis” levels (β=-0.093, SE=0.251, p=0.026).  
A significant association was also observed between DAT1 10R allele and higher 
“agitation” levels ((β=0.106, SE=0.276, 0.0062).  Finally a direct association was 
observed between DRD4 2R allele and increased sleep abnormalities (β=0.092, 
SE=0.360, p=0.0114) (Supplementary Figure 2 and Supplementary Table 2). Direct 
associations were also observed between the DAT1 10R allele and the DRD1 G allele 
and increased aberrant motor behaviour (AMB) (β=0.077, SE=0.430, p=0.0154 and 
β=-0.107, SE=0.254, p=0.0015 respectively). (Supplementary Figure 2 and 
Supplementary Table 2). The inclusion of the polymorphisms in the final model 
predicted an additional ~1%,~2% and ~1%   of the variation of the “psychosis”  
“agitation” and “moods” factors respectively but it failed to predict any additional 
variation of the “behavioural dyscontrol” factor. The model had a good fit 
(χ2=169.912, df=224, p=0.997, RMSEA=0.011, CFI=0.993) and was a significant 
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improvement to the model where no genetic variation was added (Supplementary 
Table 3). 
 
C. MIMIC model using covariates, polymorphisms and interactions between 
polymorphisms. 
The final model allowed for the investigation of specific interactions between 
different polymorphisms. We looked for interactions between the polymorphisms 
which showed significant associations with BPSD in the previous model and between 
polymorphisms that have been reported to interact with each other in previous studies 
examining BPSD or other neuropsychiatric disorders. In more detail, we investigated 
whether the DAT polymorphism interacts with DRD1 or DRD4 polymorphisms, 
whether the DRD1 polymorphism interacts with DRD3 or DRD4 polymorphisms, 
whether the COMT polymorphism interacts with HTTLPR, MAOA, or DAT 
polymorphisms, whether HTTLPR interacts with DAT, MAOA, DRD4 or STin2 
polymorphisms and finally whether the MAOA polymorphism interacts with DRD4 
polymorphism.  All of the interactions were added in the previous model where only 
direct associations with the polymorphisms were included and the final model was 
produced by using stepwise backwards regression and the Satorra-Bentler scaled chi-
square test as before. In addition to the hypothesised interactions between 
polymorphisms, we also hypothesised that the effect of the MAOA and 5HT2C 
polymorphisms may be modified by gender, since both genes are on the X 
chromosome and gender specific association have been reported for both. 
As seen in Table 1, all of the previously observed associations between 
polymorphisms and sub-phenotypes or NPI items remained significant. A very 
significant interaction was observed between the DAT1 10R and the COMT G  
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alleles. Patients carrying the 10R allele but no COMT G allele (AA carriers) had 
significantly lower “agitation” levels (β=-0.395, SE=0.563, p=0.0001) (Figure 2). As 
seen above, DAT1 10R was significantly associated with higher “agitation” levels and 
this association was independent of COMT G allele. However, absence of DAT1 10R 
allele was significantly associated with lower levels of “agitation” only in the absence 
of COMT G allele. 
 We also observed an interaction between the HTTLPR SS genotype the COMT G 
allele. Bearers of the HTTLPR SS genotype who did not bear COMT G allele had 
significantly higher “psychosis” levels (β=-0.261, SE=0.657, p=0.0255) (Figure 2). 
Another significant interaction was observed between the HTTLPR SS genotype and 
the STin2 12R allele. Patients bearing the HTTLPR SS genotype who did not carry a 
STin2 12R allele had significantly higher “psychosis” levels (β=-0.481, SE=1.103, 
p=0.0008) (Figure 2). 
Finally, a significant interaction was observed between the HTTLPR S and the DAT1 
10R alleles. Patients who carried neither the HTTLPR S allele nor the DAT1 10R 
allele had significantly lower “moods” factor level (β=-0.597, SE=0.634, p=0.0027) 
compared to those carrying both or either (Figure 2). In addition, bearers of an S allele 
who did not carry an 10R allele had significantly higher “moods” levels compared to 
carriers of an S allele who did carry a 10R allele. 
No significant interactions were observed between the rest of the hypothesised 
interactions except for a marginal interaction between DRD1 and DRD3. It was 
however not included in the final model since it did not result in significant fit 
improvement, in contrast to the rest of the interactions. 
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No interactions were observed between either the MAOA or the 5HT2C genes and 
gender except for a weak trend between the absence of high activity MAOA 4R and 
male gender with agitation (p=0.07; not included in the final model).  
In the presence of these interactions a significant association was also observed 
between the presence of the HTTLPR genotype and higher apathy (β=0.074, 
SE=0.372, p=0.033).   
The final model  is presented in Table 3 and Figure 1 and had a very good fit (χ2= 
209.72 df=274, p=0.998, RMSEA=0, CFI=1) and had a significantly better fit than 
the models which included covariates only or genetic associations with no interactions 
(Supplementary Table 3). This model explained 19.9% of “psychosis”, 11.5% of 
“agitation”, 17% of “moods” and 32% of “behavioural dyscontrol” factor, showing 
that the interactions predicted an additional 1-3% of the variation of the sub-
phenotypes.  Associations between the covariates are depicted in Figure 1 (Left side).  
Lower MMSE was significantly associated with longer disease duration, male gender 
and lack of psychotropic medication use (all p<0.0001). In addition, older age/age of 
onset is associated with female gender (p=0.0078) and with shorter disease duration 
and lack of drug use (both p<0.0001). Finally, long disease duration was associated 
with use of psychotropic medication (p= 0.0017).  
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DISCUSSION 
A number of studies have examined the association of polymorphisms in the 
serotonergic and dopaminergic system with BPSD but with conflicting results.  This 
may partly be a consequence of due of small sample sizes and differences in 
approaches employed. This study has utilised the largest AD cohort so far to 
investigate the association of polymorphic variation in the dopaminergic and 
serotenergic systems with BPSD.  It is also the first study to employ a systematic 
MIMIC approach to investigating simultaneously the association of 11 common 
polymorphisms and their interactions with both the behavioural sub-phenotypes and 
the individual NPI symptoms in AD patients, in the presence of covariates. This study 
had a minimum of 75% power to detect significant associations and interactions that 
explain at least 1% of the variance of each trait (R2) for common alleles (MAF=0.1). 
Increasing allele frequencies resulted in power estimates of almost 99%. 
This study has replicated some previously reported associations between BPSD and 
polymorphisms of the serotonergic and dopaminergic pathways but has also identified 
some novel associations. In addition, this study reports novel interactions between 
polymorphisms which may highlight epistatic effects.  
A significant association was identified between DRD1 A48G G allele and 
“psychosis” sub-phenotype. Allele G corresponds to the B1 allele in the studies 
published by Sweet et al., and Holmes et al., (15;23). It is interesting that both these 
studies identified an association between DRD1 A48G and psychotic symptoms, 
although the reported allele/genotype frequencies were not in full agreement. Here, 
we replicate the finding of Sweet and partly that of Holmes and report an association 
between the presence of allele G (GG and GA) and lower level of “psychosis” factor.  
Of note, a similar association between DRD1 A48G and psychosis has been reported 
in young adults with schizophrenia (42).  
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This is the first study to report an association of DRD1 A48G with AMB. As with the 
association with “psychosis”, allele G was associated with lower AMB symptoms.  
Although the most recent to date investigating the association of DRD1 A48G and 
BPSD (21) did not identify any significant associations, the present study employs a 
much larger cohort and in addition, the cohort  of Pritchard et al  (52) had  moderate 
cognitive impairment (mean MMSE =18.6) compared to the present cohort (Table 1).  
Of note, our study does not report an association between “psychosis” and the 5HT2A 
C102T SNP, which reported in a recent meta-analysis (43) to be significantly 
associated with psychotic symptoms in AD. 
Our findings of a significant association between DAT1 3’UTR VNTR and AMB are 
consistent with previous data (19).   In addition, we identified a significant association 
between the DAT1 10R allele and higher scores of the “agitation” sub-phenotype. The 
finding between the DAT1 VNTR and “agitation” is an intriguing one, since the 
polymorphism has been implicated in violent and anti-social behaviour in adolescents 
(44;45) and further investigation into the role of DAT1 in aggressive symptoms is 
warranted.  
The finding of an association between presence of the DRD4 2R allele and higher 
‘moods’ scores is a novel one.  Previous BPSD studies have focussed upon the 4 or 7 
alleles as risk factors (21;23), although the 2R allele has also been implicated in 
depressive symptomatology  (46) and in sleep disturbance following smoking 
cessation (47).  Pritchard et al., (2009) (57) reported an association between 
depression and the decrease of 7R allele/increase of 4R allele. They also reported an 
association between the presence of aggression/agitation and a decrease in 4R 
allele/increase in 7R allele. Here, we did not identify any significant associations with 
the 7R or 4R alleles and any symptoms/factors.  
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This study also identified a trend between the DRD3 BalI polymorphism and the 
“moods” factor.  Only one study (21) has investigated the association between DRD3 
BalI and depression,  failing however to report any significant associations. DRD3 
BalI has been previously implicated in depressive disorders, although meta-analyses 
have shown a weak association  (48).   
A number of significant interactions between different polymorphisms were also 
identified. Epistatic interactions have been rarely investigated in BPSD and only two 
study to date (23;49) has reported additive effects between COMT and HTTLPR, as 
well as between DRD1 and DRD3 on psychosis. Specific hypotheses on the effect of 
epistatic interactions on the behavioural sub-phenotypes and the individual NPI items 
were tested based on the results from the initial models and previously published 
associations.  
The effect of DAT 10R on “agitation” seemed to be modified by the COMT G allele 
whereby in the absence of COMT G allele (AA genotype), the DAT1 10R allele was 
significantly associated with lower levels of “agitation”, whereas in the presence of 
COMT G there was no significant difference in “agitation” levels between DAT1 
alleles (Figure 2c).  DAT and COMT regulate synaptic levels of dopamine in the 
brain, and thus, modulate central dopaminergic function. DAT is a presynaptic protein 
and removes dopamine from the synaptic cleft especially in subcortical regions where 
it is abundant.  In cortical regions however, where DAT is less abundant regulation of 
dopamine is achieved though intracellular degradation by COMT (50;51). Interactions 
therefore between COMT and DAT genes are of interest and have been reported in  
cortical regions in relation to schizophrenia (52) as well as on reward processing and 
cognition (53-55).  
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An interaction was also observed between the HTTLPR SS genotype and the absence 
of COMT G allele (presence of the low activity AA genotype) which was associated 
with higher “psychosis” levels.   Borroni et al., (2006) (49) reported a cumulative 
effect of COMT and HTTLPR (presence of COMT G and HTTLPR S allele) on 
“psychosis” although we failed to observe any additive effects and here “psychosis” is 
associated with the absence rather than the presence of  COMT G allele. Although 
psychotic status has been mainly associated with the presence of the high activity G 
allele, studies have reported an association with the low activity allele (56-60). Both 
SERT and COMT are responsible for the inactivation of serotonin and dopamine 
respectively and the effect of such an interaction here could be interpreted as the 
results of both genes producing an excess of monoamines in the synaptic cleft. 
Another interesting finding was that the HTTLPR SS genotype seemed to have a 
significant effect on “psychosis” only in the absence of the STin2 12R allele (a weak 
trend was observed between STin 12R  and “psychosis” prior to the addition of the 
interactions in the model; data not presented). Such a significant association is of 
interest since it highlights potential haplotypic effects. Variable patterns of LD have 
been observed between the HTTLPR and STin2 polymorphisms, although in this 
study LD was modest (D’=0.5).  This relationship is of interest because of the 
involvement of both polymorphisms with “psychosis” in BPSD (18) as well as 
schizophrenia. It is also very interesting that the recent meta-analysis on psychosis in 
AD (43) failed to support the involvement of HTTLPR with “psychotic” symptoms; a 
main contributor to this could be its potential interaction with other SERT 
polymorphisms.  
Finally an interaction was also identified between the absence of both the HTTLPR S  
and the DAT1 10R alleles which resulted in significantly lower “moods” levels (or 
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between HTTLPR S carriers carrying no DAT1 10R allele which had significantly 
higher “moods” levels). Both HTTLPR and DAT1 are responsible for the clearance of 
serotonin and dopamine respectively from the synaptic cleft and are both implicated 
in depressive disorders and response to anti-depressant treatment, and interactions 
between the two polymorphisms have been associated with harm avoidance and 
reward dependence traits  (61-66). 
The significant interactions identified in this study highlight the complexity of the 
relationships between genes of the dopaminergic and serotonergic systems and BPSD. 
Monoaminergic systems are interconnected and serotonergic projections from the 
dorsal raphe nuclei project directly to the substantia nigra and inhibit the firing of 
dopaminergic neurons (67). Interactions therefore between genes involved in the two 
systems, which may modulate behaviour, are very interesting.  However, it has to be 
highlighted that although the present study is well powered to detect these 
interactions, the combination of allele responsible for the significant effects observed 
were present in 2-7% of the patients which highlights the need for even larger cohorts.  
The significant genetic associations and interactions reported here were weak and 
individually only explained an addition 1-5% of each trait investigated, as expected 
when investigating behavioural phenotypes.  Overall the presence of covariates and 
genetic variation explained ~ 20%, 12% 17% and 32% of the variation of 
“psychosis”, “agitation”, “moods” and “behavioural dyscontrol” factors respectively 
highlighting that there is a large proportion of unexplained variation.  
This is the largest study to date investigating the association between BPSD and 
genetic variation in the serotonergic and dopaminergic systems. Single chi-square 
type analyses on the tested polymorphisms and the individual NPI symptoms have 
indicated that the MIMIC model has captured all the associations that conventional 
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methods would have captured and identified additional relationships which would 
have been otherwise missed. For example, in the MIMIC model the DRD1 G allele 
was significantly associated with “psychosis” factor after controlling for the 
individual NPI items, although regression analysis (controlling for the same 
covariates) indicated an association only with delusions. More interestingly, none of 
the individual NPI items of aggression, irritability or disinhibition was significantly 
associated with DAT 10R allele in simple regression analysis which showed non 
significant trends (p=0.103, p=0.204, p=0.256), but the association of the 10R allele 
with the “agitation” factor in the MIMIC after controlling for these variables was very 
significant (p<0.001). In addition, separate regression analyses showed that the 
associations between DRD4 2R allele with depression and anxiety (p=0.043 and 
p=0.022) were strengthened when using the latent “moods” construct in the MIMIC 
model (p=0.008) and that association of DRD4 2R with sleep disturbances also 
became slightly stronger (p=0.0175 in the MIMIC model compared to p=0.030). 
Finally the direct associations between DRD1 G and DAT 10R alleles with AMB, 
after controlling for the presence of the factors, was again strengthened  (p=0.0014 
and p=0.0149) compared to simple regression analysis (p=0.012 and p=0.092 
respectively).  
All these highlight the usefulness of using such a model which allows the modelling 
and testing of complex patterns of relationships between genes, environmental factors 
and behavioural constructs simultaneously in a joint model. In addition, using other 
methods of analysis would require multiple separate analyses. By using such a 
statistical approach, power is gained and the multiple comparison problem of standard 
regression analysis is avoided.  Multiple testing was limited here in the examination 
of different alleles of the VNTRs and in the examination of the interactions. Applying 
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correction for multiple testing, such as Bonferroni correction would result in very few 
of the significant associations passing the threshold of significance even in the case of 
the MIMIC model since the p values observed were moderate. However, when 
examining behavioural traits, moderate p values are expected and application of 
multiple testing criteria could potentially mask variants of small effect size and 
overlook significant associations. Results should however be replicated in larger 
cohorts and this may be easily achieved using the large scale genetic collaborations on 
AD.  Another advantage of structural equation modelling approaches such as MIMIC 
compared to other commonly used statistical methods is that these modelling methods 
allows the estimation and partitioning of measurement error. When measurement 
error exists, estimated parameters can be biased (68). 
In summary, the model in Figure 1 highlights the necessity of systematic statistical 
approaches such as MIMIC modelling to be used when investigating the genetic 
nature of BPSD. This model can be used in future approaches to test for the 
association of behavioural sub-phenotypes with other candidates polymorphisms in a 
simultaneous analysis of the entire system.   
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                    Table 1. Basic characteristics of the sample (n=1008). 1n=951 
 
 
Mean,(SD), range 
(n=1008) 
Age (years) 81.6 (6.5), 63-100 
Age at Onset (years) 76.1 (6.6), 60-95 
Disease Duration (months) 66.2 (39.3), 0-192 
MMSE score 12.8 (8.8), 0-28 
Females/males, (%) 726/282  (72 / 28) 
Psychotropic medication use (%) 398 (39.5%)1 
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Table 2. Polymorphisms investigated for significant associations with psychosis in 
AD 
 
Gene Chromosome Polymorphism Rs Type Genetic Model examined Frequency of 
examined allele 
5HT2A 13 102 T/C 6313 Synonymous CC+CT vs TT 0.402 
5HT2C X 68C/G- Cys23Ser 6318 Non-synonymous GG + CG vs CC 0.170 
SERT 17 40 bp insertion/deletion in promoter  VNTR SS + LS vs LL 0.423 
SERT 17 9,10 or 12 repeats of  STin.2  VNTR Presence of  12 repeats (12R) 0.592 
 
MAOA 
X 3 to 5 repeats of VNTR in promoter   VNTR 
1. Presence of  3 repeats 
2. Presence of 4 repeats 
0.329 
0.641 
DAT 
5 40 bp promoter VNTR 28363170 VNTR 
1.Presence of 10 repeats (10R) 
2.Presence of 9 repeats (9R) 
0.726 
0.269 
COMT 22 G/A- Val/158/Met 4680 Non-synonymous GG+GA vs AA 0.464 
DRD1 5 A/G 48 bp 5’ of mTSS (A48G) 4532 Promoter GG + GA vs AA 0.386 
DRD2 11 A1 allele (Taq 1) 1800479 3’ of the gene A1A1 + A1A2 vs A2A2 0.186 
DRD3 3 Bal I biallelic polymorphism  Gly9Ser 6280 Non-synonymous CC and CT vs TT 0.323 
DRD4 
11 48bp repeat in exon 3  VNTR 
1. Presence of  7 repeats 
2. Presence of 2 repeats 
0.189 
0.107 
 
. 
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Table 3. MIMIC model results: impact of genetic variation, genetic interactions, 
gender, age/age of onset, MMSE, disease duration, and psychotropic mediation use on 
the “psychosis”, “agitation”, “moods” and “behavioural dyscontrol” factors.  
Estimated direct effects of genetic variation and covariates on individual NPI items 
are noted on the bottom of the table. 
Factor 
(% variance explained) 
Significant covariates and 
polymorphisms 
β SE P 
 
Psychosis (19.9%) 
Gender 
0.125 0.227 
0.0006 
Age/Age of Onset 
0.165 0.018 
0.0001 
MMSE 
-0.121 0.014 
0.0059 
Disease duration 
0.246 0.004 
<0.0001 
Psychotropic Medication 
0.097 0.258 
0.0351 
DRD1 A48G  G  
-0.09 0.248 
0.0372 
HTTLPR SS *COMT G 
-0.261 0.657 
0.0255 
HTTLPR SS * STin2 12R 
-0.584 1.227 
0.0053 
Agitation (11.5%)1 
Disease duration 
0.197 0.003 
<0.0001 
Psychotropic Medication 
0.216 0.254 
<0.0001 
DAT1 10R repeats 
0.284 0.379 
<0.0001 
DAT 10R * COMT G  
-0.397 0.574 
0.0001 
Moods (17%) 
Gender 
0.176 0.201 
0.0025 
Psychotropic Medication 
0.236 0.237 
0.0018 
DRD4 2R 
0.189 0.275 
0.008 
SERT S * DAT 10R 
-0.601 0.632 
0.0027 
Behavioural Dyscontrol (32%)1234 
MMSE 
-0.354 0.014 
<0.0001 
Disease duration 
0.213 0.003 <0.0001 
Psychotropic Medication 
0.207 0.236 <0.0001 
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1Low MMSE had a significant effect on aggression variable after controlling for “agitation” factor (β 
=-0.146, SE=0.013, p<0.001) and higher MMSE had a significant effect on appetite abnormalities 
variable after controlling for “behavioural dyscontrol” factor (β =0.113, SE=0.021, p=0.0123). 
2Female gender was significantly associated with appetite abnormalities after controlling for 
“behavioural dyscontrol” factor (β =0.121, SE=0.328, P=0.0007) and sleeping abnormalities were 
associated with older age/age of onset (β =0.080, SE=0.360, p=0.0343). 
3 DRD1 G allele had a direct negative association with AMB (β =-0.108, SE=0.254, 0.0014), DAT 10R 
had a direct positive association with AMB (β =0.078, SE=0.431, 0.0149) and DRD4 2R had a direct 
positive association with sleep abnormalities (β =0.088, SE=0.363, p= 0.0175). 
4HTTLPR SS had a direct negative association with apathy (β=0.074, SE=0.372, p=0.033).   SE= 
Standard Error 
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Figure 1.  Multiple Indicators Multiple Causes (MIMIC) model examining the impact 
of genetic polymorphisms and their interaction in the presence of covariates.  
Measured variables are represented by a box and latent variables are represented by 
circles. Red arrows indicate a direct effect between genes or covariates and indicators 
after keeping the relevant factor constant. Bidirectional arrows on the left of the figure 
indicate correlations between covariates, whereas on the right of the NPI items they 
show error covariances. The numbers on the left of each NPI item indicate residual 
error. 
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All paths drawn indicate significant associations (p<0.05) except for association between elation and 
“behavioural dyscontrol” (p=0.20). The four factors were significantly associated with each other at the 
0.001 level (correlation of “psychosis” with “agitation”, “moods” and “behavioural dyscontrol” factors 
was ρ=0.425, ρ=0.222, ρ=0.313, correlation of “agitation” with “moods” and “behavioural dyscontrol” 
was ρ=0.303 and ρ=0.488 and correlation between “moods” and “behavioural dyscontrol” ρ=0.588 
respectively). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. a1-d1: Boxplots displaying the means of “psychosis”, “agitation” and 
“moods” factors in the presence of different allelic combinations; a2-d2: Lines 
highlight the interaction effects between different polymorphisms on the four factors. 
Differences in the directions of the factor slopes  indicates an interaction between the 
polymorphisms. The y axis represents mean factor scores for the different genotypes 
on the x axis. 
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b1               b2  
c1              c2  
d1              d2  
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